September 6th 2025
Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Dr Sibel Blau Outlines Changes to Her Practice to Prepare for OCM
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
Dr Marcus Neubauer Discusses the Evolution of Care Teams in Oncology
Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties
Nobel Prize Winner Dr James Allison on the Impact His Work Has Made
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers